Patents by Inventor Gregory Henkel

Gregory Henkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230303569
    Abstract: The invention relates to compounds of structural formula 1 wherein A is independently N or C—R3, R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C6) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: May 11, 2023
    Publication date: September 28, 2023
    Applicant: Arisan Therapeutics Inc.
    Inventors: Nadezda Sokolova, Kenneth McCormack, Gregory Henkel, Vidyasagar Reddy Gantla, Eric Brown
  • Patent number: 11548893
    Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 10, 2023
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla
  • Publication number: 20220281825
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: April 21, 2022
    Publication date: September 8, 2022
    Applicant: Arisan Therapeutics Inc.
    Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
  • Publication number: 20220193038
    Abstract: Compounds as exemplified by compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.
    Type: Application
    Filed: December 3, 2019
    Publication date: June 23, 2022
    Applicant: Arisan Therapeutics Inc.
    Inventors: Eric Brown, Vidyasagar Reddy Gantla, Nadezda Sokolova, Michael Bruno Plewe, Gregory Henkel, Kenneth McCormack
  • Patent number: 11352328
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 7, 2022
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadzeda V. Sokolova, Young-Jun Shin
  • Publication number: 20210171521
    Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.
    Type: Application
    Filed: July 11, 2018
    Publication date: June 10, 2021
    Applicant: Arisan Therapeutics, Inc.
    Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla
  • Publication number: 20200017514
    Abstract: Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R1, R2, R3, X and Y are defined in the specification.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 16, 2020
    Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadezda Sokolova
  • Publication number: 20190308938
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: July 7, 2017
    Publication date: October 10, 2019
    Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
  • Publication number: 20140364450
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Application
    Filed: April 15, 2014
    Publication date: December 11, 2014
    Inventors: Juan-Miguel Jimenez, Philip Collier, Gregory Henkel, Michael Liu, Timothy Neuberger, Jeremy Green
  • Publication number: 20140194444
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 10, 2014
    Inventors: Juan-Miguel Jimenez, Andrew Miller, Jeremy Green, Huai Gao, Gregory Henkel, Michael Liu, Timothy Neuberger
  • Patent number: 8735593
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: May 27, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger
  • Patent number: 8664219
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: March 4, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Juan-Miguel Jimenez, Andrew Miller, Jeremy Green, Huai Gao, Gregory Henkel, Michael Liu, Timothy Neuberger
  • Publication number: 20130245273
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Application
    Filed: March 5, 2013
    Publication date: September 19, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger
  • Patent number: 8518953
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: August 27, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Albert Pierce, Jon Come, John Court, Gregory Henkel, Michael Liu, Timothy Neuberger, Huai Gao
  • Patent number: 8410133
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds, the methods of using the aforementioned compounds, and compounds in the treatment of various diseases, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: April 2, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger
  • Publication number: 20110020377
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Application
    Filed: June 2, 2010
    Publication date: January 27, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Albert Pierce, Jon Come, John Court, Gregory Henkel, Michael Liu, Timothy Neuberger, Huai Gao
  • Publication number: 20110020376
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Application
    Filed: June 2, 2010
    Publication date: January 27, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Juan-Miguel Jimenez, Andrew Miller, Jeremy Green, Huai Gao, Gregory Henkel, Michael Liu, Timothy Neuberger
  • Publication number: 20110021559
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
    Type: Application
    Filed: June 2, 2010
    Publication date: January 27, 2011
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Juan-Miguel Jimenez, Philip Collier, Jeremy Green, Gregory Henkel, Michael Liu, Timothy Neuberger